» Articles » PMID: 16104635

DOT and Timely Treatment Completion Among Asian-born Immigrant Tuberculosis Patients

Overview
Specialty Pulmonary Medicine
Date 2005 Aug 18
PMID 16104635
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Setting: A large urban tuberculosis (TB) control program.

Objectives: To identify factors associated with directly observed therapy (DOT) participation and to quantify how early use of DOT affected treatment duration.

Design: A retrospective study of 731 Asian-born patients with drug-susceptible Mycobacterium tuberculosis isolates who were verified in New York City between 1993 and 1997 and completed treatment.

Results: Overall, 297 (41%) of 731 patients in the study participated in DOT for some or all of their TB treatment. DOT participation was significantly associated with TB disease in a pulmonary site (adjusted odds ratio [aOR] 2.85, 95% CI 1.86-4.35), more recent year of diagnosis (aOR 1.70, 95% CI 1.50-1.94) and male sex (aOR 1.86, 95% CI 1.30-2.66). Patients who received > or = 70% of their TB treatment at a health department chest clinic were also significantly more likely to participate in DOT (aOR 3.83, 95% CI 2.55-5.74). Among 297 DOT patients, those who completed treatment by 9 months received a greater amount of treatment by DOT during the first 4 months of treatment than those who took longer to complete treatment.

Conclusion: Earlier DOT participation can lead to overall shorter treatment duration. Health care providers should encourage TB patients to participate in DOT as early as possible in their TB treatment.

Citing Articles

Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman S, Alipanah N, Barry P, Brozek J, Cattamanchi A Clin Infect Dis. 2016; 63(7):853-67.

PMID: 27621353 PMC: 6366011. DOI: 10.1093/cid/ciw566.


Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman S, Alipanah N, Barry P, Brozek J, Cattamanchi A Clin Infect Dis. 2016; 63(7):e147-e195.

PMID: 27516382 PMC: 6590850. DOI: 10.1093/cid/ciw376.